Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and NanoString Technologies Inc. (NASDAQ:NSTG), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apellis Pharmaceuticals Inc.||N/A||0.00||127.50M||-2.05||0.00|
|NanoString Technologies Inc.||106.73M||8.87||77.40M||-0.98||0.00|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 provides the return on assets, net margins and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Apellis Pharmaceuticals Inc.||0.00%||-48.3%||-39.9%|
|NanoString Technologies Inc.||-72.52%||-206.8%||-50.8%|
The Current Ratio and a Quick Ratio of Apellis Pharmaceuticals Inc. are 14.9 and 14.9. Competitively, NanoString Technologies Inc. has 3.6 and 3.2 for Current and Quick Ratio. Apellis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than NanoString Technologies Inc.
The next table highlights the delivered recommendations and ratings for Apellis Pharmaceuticals Inc. and NanoString Technologies Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Apellis Pharmaceuticals Inc.||0||0||1||3.00|
|NanoString Technologies Inc.||0||1||2||2.67|
The average target price of Apellis Pharmaceuticals Inc. is $45, with potential upside of 134.38%. Competitively the average target price of NanoString Technologies Inc. is $29, which is potential 7.37% upside. Based on the analysts view we can conclude, Apellis Pharmaceuticals Inc. is looking more favorable than NanoString Technologies Inc.
Institutional & Insider Ownership
The shares of both Apellis Pharmaceuticals Inc. and NanoString Technologies Inc. are owned by institutional investors at 59.3% and 92.4% respectively. Insiders owned 20.7% of Apellis Pharmaceuticals Inc. shares. Insiders Comparatively, owned 13.7% of NanoString Technologies Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Apellis Pharmaceuticals Inc.||23.33%||31.79%||16.7%||-2.95%||-0.43%||39.88%|
|NanoString Technologies Inc.||12.71%||20.46%||54.59%||69.56%||303.46%||80.65%|
For the past year Apellis Pharmaceuticals Inc. was less bullish than NanoString Technologies Inc.
Apellis Pharmaceuticals Inc. beats on 6 of the 11 factors NanoString Technologies Inc.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.
NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.